Chen Schor is recorded as CEO at Adicet Bio, Inc. (ACET) and Board Member at Karyopharm Therapeutics Inc. (KPTI). The newest filing on record that lists Chen Schor as CEO at Adicet Bio, Inc. (ACET) is dated April 23, 2024. The newest filing on record that lists Chen Schor as Board Member at Karyopharm Therapeutics Inc. (KPTI) is dated April 13, 2026. Karyopharm Therapeutics Inc. reported in an 8-K filed May 31, 2024 that Chen Schor was appointed Class II director, effective May 29, 2024. The proxy statement of Adicet Bio, Inc. reports total compensation of $1,465,747 for Chen Schor in fiscal 2025, including a base salary of $646,294. Disclosed compensation is on record for 8 fiscal years. Chen Schor has spoken on 2 investor events across 1 company, most recently for Adicet Bio, Inc. on August 11, 2026. Adicet Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Karyopharm Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Adicet Bio, Inc. includes Nick Harvey (CFO), Stewart Abbot (COO), Stewart Abbot, Ph.D. (COO) and 7 others.
“The Company's stockholders elected Deepika R. Pakianathan, Richard Paulson and Chen Schor as Class II directors, each to serve on the Board for a three-year term until the 2027 annual meeting of stockholders and until his or her resignation or removal or until his or her successor is duly elected and qualified.”
Karyopharm Therapeutics Inc. Form 8-K, filed May 31, 2024
· Read the filing
Chen Schor on recent calls
“First of all, John, thank you very much for inviting us. Very timely. We expect to have very, very significant disclosures in the very near future. So excited to be here and talk about what we expect to, the data we expect to share.”
